NCT03837821View on ClinicalTrials.gov

(CLONEVO): Cell cycLe inhbitiON to Target the EVolution of UrOthelial Cancer

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 5, 2019

Primary Completion Date

July 2, 2024

Study Completion Date

December 31, 2025

Conditions
Bladder Cancer
Interventions
DRUG

Abemaciclib

Abemaciclib 200 mg oral, every 12 hours

Trial Locations (4)

10065

Weill Cornell Medicine, New York

11217

NewYork-Presbyterian Brooklyn Methodist Hospital, Brooklyn

33612

Moffitt Cancer Center, Tampa

75390

UT Southwestern Medical Center - Simmons Comprehensive Cancer Center, Dallas

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Weill Medical College of Cornell University

OTHER